Antiplatelet Therapy in Patients With COVID-19—More Is Less?
Bart Spaetgens, Magdolna Nagy, Hugo Ten Cate
Abstract
Because venous and arterial thromboembolism are common among patients hospitalized with COVID-19, 1,2 anticoagulant therapies were among the first to be evaluated in clinical trials to improve outcomes in moderately ill patients hospitalized with COVID-19. These studies have yielded thus far somewhat mixed results, varying from beneficial effects of therapeutic doses of low-molecularweight heparin in the ATTACC, ACTIV-4a, and REMAP-CAP trials 3 to no difference between therapeutic and prophylactic doses of low-molecular-weight heparin in the INSPIRATION, ACTION, and RAPID trials. [4] 5][6] Therefore, it remains to be determined whether the addition of antiplatelet therapy will yield different results.